Fractyl Health (NASDAQ:GUTS) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS

by · The Cerbat Gem

Fractyl Health (NASDAQ:GUTS – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23, FiscalAI reports.

Fractyl Health Price Performance

NASDAQ GUTS traded down $0.04 on Tuesday, reaching $0.73. The company’s stock had a trading volume of 1,955,572 shares, compared to its average volume of 4,395,596. The firm has a market cap of $116.45 million, a PE ratio of -0.40 and a beta of 2.11. The business has a 50-day moving average price of $0.53 and a 200 day moving average price of $1.14. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $8.00 to $2.00 in a report on Thursday, January 29th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Friday, April 24th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Fractyl Health presently has a consensus rating of “Hold” and a consensus price target of $5.40.

Read Our Latest Report on Fractyl Health

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the second quarter worth approximately $31,000. Jump Financial LLC acquired a new position in shares of Fractyl Health during the fourth quarter worth approximately $57,000. Scientech Research LLC acquired a new position in shares of Fractyl Health during the third quarter worth approximately $49,000. Prelude Capital Management LLC acquired a new position in shares of Fractyl Health during the third quarter worth approximately $55,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Fractyl Health during the fourth quarter worth approximately $85,000.

About Fractyl Health

(Get Free Report)

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

Recommended Stories